Cargando…
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
Autores principales: | Nolan, L, Johnson, P W M, Ganesan, A, Packham, G, Crabb, S J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528143/ https://www.ncbi.nlm.nih.gov/pubmed/18728657 http://dx.doi.org/10.1038/sj.bjc.6604557 |
Ejemplares similares
-
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
por: Groselj, B, et al.
Publicado: (2013) -
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
por: Ceccacci, Elena, et al.
Publicado: (2016) -
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
por: Schizas, Dimitrios, et al.
Publicado: (2018) -
Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
por: Sim, Wynne, et al.
Publicado: (2022) -
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)